AttendMe Owl Logo
AttendMe
Evidence Evolution
NeurologyNeurology

How This Evidence Evolved

Status Epilepticus Second-Line Agents

Three drugs, one answer

14.5

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

The 1998 VA Cooperative Study compared four intravenous regimens for generalized convulsive status epilepticus. In verified overt cases, treatment success was 64.9% with lorazepam, 58.2% with phenobarbital, 55.8% with diazepam plus phenytoin and 43.6% with phenytoin. Success required seizure cessation within 20 minutes without recurrence for the next 40 minutes. Lorazepam was superior to phenytoin, but not more efficacious than phenobarbital or diazepam plus phenytoin. This initial-treatment comparison differs from later trials after benzodiazepine failure.
Proof

Landmark RCTs and pivotal trials that established the evidence base

ESETT (2019) randomized 384 children and adults with benzodiazepine-refractory convulsive status epilepticus to levetiracetam, fosphenytoin or valproate. Absence of clinically evident seizures plus improved consciousness by 60 minutes, without additional anticonvulsant medication, occurred in 47%, 45% and 46%, respectively. A prespecified interim rule stopped the trial for futility of identifying a superior or inferior drug. Similar observed outcomes do not establish formal equivalence. Adverse-event incidences were similar.
Extension

Follow-up studies, subgroup analyses, and real-world validation

ESETT subsequently compared intravenous agents for benzodiazepine-refractory convulsive status epilepticus.
Guidelines

Integration into clinical practice guidelines and recommendations

AES 2016 evaluated anticonvulsant efficacy and safety in children and adults with convulsive status epilepticus. ESETT later compared levetiracetam, fosphenytoin and valproate after benzodiazepine failure. Its combined clinical endpoint was achieved in approximately half of patients with each drug; its futility stopping rule did not establish formal equivalence.
AES Status Epilepticus Guidelines
Now

Current standard of care and ongoing research directions

ESETT supports levetiracetam, fosphenytoin and valproate as studied options after benzodiazepine failure, with similar observed efficacy and adverse-event incidences. Its superiority-futility stopping rule did not prove equivalence. Patient factors, contraindications and availability remain relevant when applying these results. Because the combined endpoint was achieved in approximately half of patients, subsequent treatment remains an important clinical question.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the best second-line drug for status epilepticus?+
ESETT (2019; 384 patients) found no clinically evident seizures plus improved consciousness by 60 minutes, without extra anticonvulsant medication, in 47% with levetiracetam, 45% with fosphenytoin and 46% with valproate. It stopped for futility of finding superiority or inferiority; this did not prove equivalence.
Can status epilepticus be treated before reaching the hospital?+
Yes.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026